Tech Company Financing Transactions
Calidi Biotherapeutics Funding Round
Calidi Biotherapeutics closed a $25 million Series B funding round on 6/23/2023. Investors included Calidi Cure, private investors and Jackson Investment Group.
Transaction Overview
Company Name
Announced On
6/23/2023
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series B
Investors
Proceeds Purpose
Calidi's technology utilizing stem cells to deliver and potentiate oncolytic viruses is a novel and differentiated approach to fighting cancer. I am grateful to our new and existing investors for their support of our mission and look forward to using this funding to continue pushing the frontiers of stem cells and oncolytic viral therapies and making a difference in the lives of patients.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10210 Campus Point Dr. 150
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the utilization of oncolytic viruses through an allogeneic cell-based delivery system. Calidi Biotherapeutics is advancing this potent stem cell and oncolytic virus (SN-V1c-vaccinia virus) combination for use in multiple difficult-to-treat oncology indications.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 6/23/2023: PM Pediatrics venture capital transaction
Next: 6/23/2023: Continuum Space Systems venture capital transaction
Share this article
Where The Data Comes From
We document funding rounds that are announced publicly. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs